

Special Issue

Molecular Research of Neurological and Psychiatric Disorders

Message from the Guest Editor

The Special Issue will focus on the latest molecular biology techniques, genetic findings and biochemical pathways involved in disorders such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, schizophrenia, depression, and bipolar disorder and autism spectrum disorders. An emphasis will be placed on cutting-edge research that unveils the role of genetic variations, epigenetic modifications, neurotransmitter dysregulation and protein misfolding in the pathogenesis of these complex diseases. By highlighting innovative studies on molecular diagnostics, biomarker discovery and the development of novel therapeutic strategies, this Special Issue seeks to bridge the gap between molecular insights and clinical applications, offering hope for patients and advancements in personalized medicine. Through interdisciplinary research and collaboration, it aims to contribute significantly to the understanding of the molecular basis of neurological and psychiatric disorders, paving the way for more effective treatments and interventions.

Guest Editor

Dr. Yuen Gao

Department of Physiology, College of Nature Sciences, Michigan State University, East Lansing, MI 48824, USA

Deadline for manuscript submissions

30 November 2025



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/si/201430

Biomedicines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2024).